ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
480 articles with ImmunoGen Inc.
-
ImmunoGen, Inc. Announces Addition of Stephen C. McCluski to its Board of Directors
4/27/2007
-
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2007 Financial Results
4/26/2007
-
ImmunoGen, Inc. Announces Departure of Walter Blattler
3/7/2007
-
ImmunoGen, Inc. To Present at the Cowen and Company 27th Annual Health Care Conference
3/6/2007
-
ImmunoGen, Inc. Announces Webcast Of Presentation At The Susquehanna Financial Group's SIGnificant Investment Options In Healthcare Conference
2/22/2007
-
ImmunoGen, Inc. Announces Webcast Of Presentation At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2007
2/6/2007
-
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2007 Financial Results
2/2/2007
-
ImmunoGen, Inc. Announces Addition Of Howard Pien To Its Board Of Directors
1/31/2007
-
ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2007 Financial Results
1/25/2007
-
ImmunoGen, Inc. Announces Presentation Of First Clinical Data For Genentech, Inc.'s Trastuzumab-MCC-DM1
12/15/2006
-
ImmunoGen, Inc. Announces Presentation At American Society of Hematology Of Encouraging Findings With HuN901-DM1 For The Treatment Of Multiple Myeloma
12/11/2006
-
ImmunoGen, Inc. Announces Webcast Of Panel Session At The 2006 RBC Capital Markets Healthcare Conference
12/6/2006
-
ImmunoGen, Inc. Announces Webcast Of Presentation At The Lazard Capital Markets Third Annual Life Sciences Conference
11/21/2006
-
ImmunoGen, Inc. Announces Presentation Of HuN901-DM1 Clinical Data At EORTC-NCI-AACR Conference Showing Compound Is Well Tolerated And Demonstrates Anticancer Activity
11/10/2006
-
ImmunoGen, Inc. Announces Presentation Of HuC242-DM4 Clinical Data At EORTC-NCI-AACR Conference
11/8/2006
-
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2007 Financial Results
11/3/2006
-
ImmunoGen, Inc. Announces Webcast Of Presentation At The Cowen & Co. 7th Annual Global Health Care Conference
11/1/2006
-
ImmunoGen, Inc. Announces Conference Call To Discuss Its First Quarter Fiscal Year 2007 Financial Results
10/26/2006
-
Sanofi-Aventis (France) Licenses Broader Access To ImmunoGen, Inc.'s Antibody Humanization Technology
10/18/2006
-
ImmunoGen, Inc. Announces Webcast Of Its Presentation At The Biotechnology Industry Organization (BIO) Investor Forum 2006
10/12/2006